BerGenBio Provides Interim Update on Phase II Clinical Programme With Selective Oral AXL Inhibitor Bemcentinib

BerGenBio Provides Interim Update on Phase II Clinical Programme With Selective Oral AXL Inhibitor Bemcentinib

CHICAGO, June 3, 2018 /PRNewswire/ — BerGenBio ASA (OSE:BGBIO) announces that interim data from its Phase II clinical development programme with bemcentinib, a selective AXL inhibitor, was presented at a reception hosted yesterday by the company in Chicago, IL, USA. The reception, which

BerGenBio to Present Interim Clinical and Biomarker Data With Selective AXL Inhibitor Bemcentinib in AML and MDS at EHA

Bergen, Norway, 18 May 2018 – BerGenBio ASA (OSE: BGBIO) announces that the company and its collaborators will present interim clinical data from its Phase II clinical development programme with bemcentinib, a selective, oral AXL inhibitor, in acute myeloid leukaemia (AML)